Image credit: Rao lab
Patterns of brain activity can be used to forecast seizure risk in epilepsy patients several days in advance, according to a new analysis of data obtained from clinically approved brain implants by neuroscientists at UC San Francisco, the University of Bern and the University of Geneva.
“For 40 years, efforts to predict seizures have focused on developing early warning systems, which at best could give patients warnings just a few seconds or minutes in advance of a seizure. This is the first time anyone has been able to forecast seizures reliably several days in advance, which could really allow people to start planning their lives around when they’re at high or low risk,” said Vikram Rao, MD, PhD, a neurologist at the UCSF Epilepsy Center, part of the UCSF Helen Diller Medical Center at Parnassus Heights. Rao was co-senior author of the new study, which was published Dec. 17, 2020, in
Source:
Highlights
National Institute of Health has discovered how a set of high-frequency brain waves may help us spot differences between the past and the present.
The study shows how the human brain uses certain neural activity patterns to compare our expectations with the present.
These results will help us better understand how the brain portrays reality under healthy and disease conditions
Washington: In a study involving epilepsy patients, National Institutes of Health has discovered how a set of high-frequency brain waves may help us spot these kinds of differences between the past and the present. Our results suggest that every experience we store into memory can be used to set our expectations and predictions for the future, Kareem Zaghloul, M.D., Ph.D., principal investigator at the NIH s National Institute of Neurological Disorders and Stroke (NINDS), and senior author of the study published in Nature Communications.
Share this article
Share this article
LA JOLLA, Calif., Dec. 15, 2020 /PRNewswire/ Alume Biosciences, Inc. (Alume) announced today that it has been awarded a $2.5M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). This grant will support Alume s clinical development of its novel nerve illumination technology in surgery. The Principal Investigators on this grant are Michael Whitney, PhD, Scientific Co-Founder and Vice President of Discovery and Brett Berman, MD, Co-Founder and Chief Medical Officer at Alume.
Alume previously received a Phase I SBIR grant in 2019 from the NINDS to develop nerve illumination agents for surgical use. The Phase II SBIR grant is a follow-on 2–year award that will support testing of Alume s fluorescent nerve targeting agent in an ongoing Phase 1/2 clinical trial in patients undergoing Head and Neck Surgery. Alume s technolog
Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital has selected Seelos’ Phase IIbIII study of SLS-005 to be included in the HEALEY ALS Platform Trial, the first ever platform trial for the treatment of …
– Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital has selected Seelos’ Phase IIbIII study of SLS-005 (trehalose) to be included in the HEALEY ALS Platform Trial, the first ever platform trial for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).
What would the world look like without our seniors? oleantimesherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oleantimesherald.com Daily Mail and Mail on Sunday newspapers.